On July 13, 2026, Alto Neuroscience, Inc. (the "Company") announced that, based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and restricted cash as of June 30, 2026 may differ from these amounts after it completes its comprehensive accounting procedures for the quarter ended June 30, 2026, and any such differences may be material.